Literature DB >> 25350069

gDNA enrichment by a transposase-based technology for NGS analysis of the whole sequence of BRCA1, BRCA2, and 9 genes involved in DNA damage repair.

Sandy Chevrier1, Romain Boidot2.   

Abstract

The widespread use of Next Generation Sequencing has opened up new avenues for cancer research and diagnosis. NGS will bring huge amounts of new data on cancer, and especially cancer genetics. Current knowledge and future discoveries will make it necessary to study a huge number of genes that could be involved in a genetic predisposition to cancer. In this regard, we developed a Nextera design to study 11 complete genes involved in DNA damage repair. This protocol was developed to safely study 11 genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, PALB2, RAD50, RAD51C, RAD80, and TP53) from promoter to 3'-UTR in 24 patients simultaneously. This protocol, based on transposase technology and gDNA enrichment, gives a great advantage in terms of time for the genetic diagnosis thanks to sample multiplexing. This protocol can be safely used with blood gDNA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25350069      PMCID: PMC4828150          DOI: 10.3791/51902

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  19 in total

1.  Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.

Authors:  Imma Hernan; Emma Borràs; Miguel de Sousa Dias; María José Gamundi; Begoña Mañé; Gemma Llort; José A G Agúndez; Miguel Blanca; Miguel Carballo
Journal:  J Mol Diagn       Date:  2012-03-16       Impact factor: 5.568

2.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

3.  PALB2 mutations in European familial pancreatic cancer families.

Authors:  E P Slater; P Langer; E Niemczyk; K Strauch; J Butler; N Habbe; J P Neoptolemos; W Greenhalf; D K Bartsch
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

4.  BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy.

Authors:  Olga Anczuków; Monique Buisson; Mélanie Léoné; Christine Coutanson; Christine Lasset; Alain Calender; Olga M Sinilnikova; Sylvie Mazoyer
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

5.  Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.

Authors:  Brooke L Brewster; Francesca Rossiello; Juliet D French; Stacey L Edwards; Ming Wong; Ania Wronski; Phillip Whiley; Nic Waddell; Xiaowei Chen; Betsy Bove; John L Hopper; Esther M John; Irene Andrulis; Mary Daly; Sara Volorio; Loris Bernard; Bernard Peissel; Siranoush Manoukian; Monica Barile; Sara Pizzamiglio; Paolo Verderio; Amanda B Spurdle; Paolo Radice; Andrew K Godwin; Melissa C Southey; Melissa A Brown; Paolo Peterlongo
Journal:  Hum Mutat       Date:  2012-08-02       Impact factor: 4.878

6.  First evidence for the contribution of the genetic variations of BRCA1-interacting protein 1 (BRIP1) to the genetic susceptibility of cervical cancer.

Authors:  X D Ma; G Q Cai; W Zou; Y H Huang; J R Zhang; D T Wang; B L Chen
Journal:  Gene       Date:  2013-05-01       Impact factor: 3.688

7.  Systematic comparison of three methods for fragmentation of long-range PCR products for next generation sequencing.

Authors:  Ellen Knierim; Barbara Lucke; Jana Marie Schwarz; Markus Schuelke; Dominik Seelow
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

Review 8.  Technical and implementation issues in using next-generation sequencing of cancers in clinical practice.

Authors:  D Ulahannan; M B Kovac; P J Mulholland; J-B Cazier; I Tomlinson
Journal:  Br J Cancer       Date:  2013-07-25       Impact factor: 7.640

9.  Detection of novel mutations that cause autosomal dominant retinitis pigmentosa in candidate genes by long-range PCR amplification and next-generation sequencing.

Authors:  Miguel de Sousa Dias; Imma Hernan; Beatriz Pascual; Emma Borràs; Begoña Mañé; Maria José Gamundi; Miguel Carballo
Journal:  Mol Vis       Date:  2013-03-21       Impact factor: 2.367

10.  PALB2 and breast cancer: ready for clinical translation!

Authors:  Melissa C Southey; Zhi L Teo; Ingrid Winship
Journal:  Appl Clin Genet       Date:  2013-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.